



PRESTO

P2X REceptorS as Therapeutic Opportunity

PUBLICATIONS

1. Sivcev, S., Kudova, E., Zemkova, H: Neurosteroids as positive and negative allosteric modulators of ligand-gated ion channels: P2X receptor perspective. **Neuropharmacology**, **2023**, doi: 10.1016/j.neuropharm.2023.109542.
2. Falzoni S, Vultaggio-Poma V, Chiozzi P, Tarantini M, Adinolfi E, Boldrini P, Giuliani AL, Morciano G, Tang Y, Gorecki DC, Di Virgilio F. The P2X7 Receptor is a Master Regulator of Microparticle and Mitochondria Exchange in Mouse Microglia. **Function (Oxf)**, **2024**, 5:zqae019. doi: 10.1093/function/zqae019.
3. Tattersall L, Adinolfi E, Antonioli L, Agrawal A. Preclinical and clinical aspects of P2X receptors as a common route in different diseases: A meeting report. **Purinergic Signalling**, **2024**, doi: 10.1007/s11302-024-09994-x.
4. Szymczak B, Pegoraro A, De Marchi E, Grignolo M, Maciejewski B, Czarnecka J, Adinolfi E, Roszek K. Retinoic acid-induced alterations enhance eATP-mediated anti-cancer effects in glioma cells: Implications for P2X7 receptor variants as key players. **Biochimica et Biophysica Acta Molecular Basis of Disease**, **2024**, doi: 10.1016/j.bbadis.2024.167611.
5. Alnassar N, Hajto J, Rumney RMH, Verma S, Borczyk M, Saha C, Kanczler J, Butt AM, Occhipinti A, Pomeroy J, Angione C, Korostynski M, Górecki DC. Ablation of the dystrophin Dp71f alternative C-terminal variant increases sarcoma tumour cell aggressiveness. **Human Molecular Genetics**, **2024**, doi: 10.1093/hmg/ddae094.
6. Rumney RMH, Pomeroy J, Górecki DC. Investigating the Involvement of C-X-C Motif Chemokine 5 and P2X7 Purinoceptor in Ectopic Calcification in Mouse Models of Duchenne Muscular Dystrophy. **Journal of Cellular Biochemistry**, **2024**, doi: 10.1002/jcb.30617.
7. Carracedo S, Launay A, Dechelle-Marquet PA, Faivre E, Blum D, Delarasse C, Boué-Grabot E. Purinergic-associated immune responses in neurodegenerative diseases. **Progress in Neurobiology**, **2024**, doi: 10.1016/j.pneurobio.2024.102693. Review.
8. Orehek S, Ramuta TŽ, Lainšček D, Malenšek Š, Šala M, Benčina M, Jerala R, Hafner-Bratkovič I. Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors. **Nature Communications**, **2024**, doi: 10.1038/s41467-024-55083-3.
9. Bedeschi M, Agrawal A, Adinolfi E, Tesei A, Vouret-Craviari V. A Step-by-Step Protocol Based on Data Mining to Explore Purinergic Signalling in Glioblastoma. **Purinergic Signalling**, **2025**. doi: 10.1007/s11302-025-10080-z.
10. Long-Mira E, Bontoux C, Rignol G, Hofman V, Lassalle S, Benzaquen J, Boutros J, Lavée-Moret S, Zahaf K, Lespinet-Fabre V, Bordone O, Maistre S, Bonnetaud C, Cohen C, Berthet JP, Marquette CH, Vouret-Craviari V, Ilić M, Hofman P. Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations. **Cancers (Basel)**, **2025**, doi: 10.3390/cancers17061034.
11. Pomeroy J, Borczyk M, Kawalec M, Hajto J, Carlson E, Svärd S, Verma S, Bareke E, Boratyńska-Jasińska A, Dymkowska D, Mellado-Ibáñez A, Laight D, Zabłocki K, Occhipinti A, Majewska L, Angione C, Majewski J, Yegutkin GG, Korostynski M, Zabłocka B, Górecki DC. Spatiotemporal diversity in molecular and functional abnormalities in the mdx dystrophic brain. **Molecular Medicine**, **2025**, doi: 10.1186/s10020-025-01109-5.



PRESTO

P2X REceptorS as Therapeutic Opportunity

12. Boršić E, Ramuta TŽ, Orehek S, Kreft ME, Geyer M, Jerala R, Hafner-Bratkovič I. Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. **Nature Communications**, **2025**, doi: 10.1038/s41467-025-60277-4.
13. Gorecki DC, Patel AM, Pomeroy J, Verkhatsky A. Deficient Astrocyte Homeostatic Support Contributes to Brain Impairment in Duchenne Muscular Dystrophy. **Neurochemical Research**, **2025**, doi: 10.1007/s11064-025-04464-1. Review.
14. Cihakova J, Ivetic M, Zemkova H. Cell Type-Specific Expression of Purinergic P2X Receptors in the Hypothalamus. **International Journal of Molecular Sciences**, **2025**, doi: 10.3390/ijms26115007.
15. Dal Ben D, Buccioni M, Lambertucci C, Francucci B, Smirnov A, Spinaci A, Marucci G, Volpini R. Radioligands Targeting the Purinergic P2X Receptors. **Cells**, **2025**, doi: 10.3390/cells14130984. Review.
16. Zuanon M, Brancale A, Young MT. Identification of New Human P2X7 Antagonists Using Ligand- and Structure-Based Virtual Screening. **Journal of Chemical Information and Modeling**, **2025**, doi: 10.1021/acs.jcim.5c00552.
17. Valencia I, Pastor-Martínez A, Decouty-Pérez C, Lopez-Rodriguez AB, Álvarez-Rubal M, Ramos E, Calzaferri F, Zamorano-Fernández J, Giner-García J, Palpán-Flores AJ, Rodríguez-Domínguez V, Rodríguez de Cía J, Hernández-García BJ, Romero A, de los Ríos C, Egea J. Pharmacological evaluation of non-nucleotide purine derivatives as P2X7R antagonists for the treatment of neuroinflammation in traumatic brain injury. **British Journal of Pharmacology**, **2025**; doi: 10.1111/bph.70108.
18. (preprint) Paniagua-Herranz L, Serrano-López J, Llorente-Sáez C, Pérez-Sanz ML, de Agustín-Durán D, Duart-Abadía P, Domingo-Muelas A, Vincelle-Nieto A, Bragado P, Manzano-Franco D, Arribas-Blázquez M, Gallego L, Olivos-Ore LA, Gascón S, Gutierrez-Uzquiza A, Perez-Sen R, Delicado EG, Gomez-Villafueres R, Reyes-Palomares A, Artalejo AR, Fariñas I, Ortega F. Purinergic Receptor P2Y13 Controls Activation and Mode of Division in Subependymal Adult Neural Stem Cells. **bioRxiv**, **2024.11.29.626065**, doi: <https://doi.org/10.1101/2024.11.29.626065>.
19. Serrano-López J, Llorente-Sáez C, Pérez-Sen R, Delicado EG, Ortega F, Gómez-Villafuertes R. Intracellular Calcium Recording and Immunostaining of Single Neural Populations In Vitro. **Methods in Molecular Biology**, **2025**, (volume 2899), doi: 10.1007/978-1-0716-4386-0_19.
20. Llorente-Sáez C, Serrano-López J, Delicado EG, Pérez-Sen R, Gómez-Villafuertes R, Ortega F. Low-Density Primary Cell Culture of Postnatal Murine Cerebellar Progenitors In Vitro. **Methods in Molecular Biology**, **2025**, (volume 2899), doi: 10.1007/978-1-0716-4386-0_3.

List published in July 2025.

Year 3: Grant Period, November 1st, 2024 – October 31st, 2025